Last reviewed · How we verify

Hycodan — Competitive Intelligence Brief

Hycodan (METHYLHOMATROPINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: methylhomatropine. Area: Gastroenterology.

marketed methylhomatropine Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Hycodan (METHYLHOMATROPINE) — Endo. Hycodan works by affecting the nervous system to reduce cough and relieve symptoms of irritable bowel syndrome and peptic ulcer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hycodan TARGET METHYLHOMATROPINE Endo marketed methylhomatropine 1943-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (methylhomatropine class)

  1. Endo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hycodan — Competitive Intelligence Brief. https://druglandscape.com/ci/methylhomatropine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: